Cancer Family
Respiratory System Neoplasm
CI-CAN-00000049Explore in graph →
Non-malignant2,725 active trials51 approved drugs619 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000049Explore in graph →
Clinical trials
11,608 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02768558 | Cisplatin and Etoposide Plus Radiation Followed By Nivolumab/Placebo For Locally Advanced NSCLC | terminated | Phase 3 | 20 | RTOG Foundation, Inc.OTHER | 1 | Jun 2, 2021 | clinicaltrials |
| NCT02644252 | Tocotrienol as a Nutritional Supplement in Patients With Advanced Lung Cancer(Toco-Pulm) | terminated | Phase 3 | 79 | Vejle HospitalOTHER | 1 | May 3, 2021 | clinicaltrials |
| NCT01244191 | Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer | terminated | Phase 3 | 1,048 | Daiichi SankyoINDUSTRY | 23 | Apr 6, 2021 | clinicaltrials |
| NCT02893332 | Stereotactic Body Radiation Therapy (SBRT) in Newly Diagnosed Advanced Staged Lung Adenocarcinoma (Sindas)(Sindas) | terminated | Phase 3 | 200 | Sichuan Provincial People's HospitalOTHER | 1 | Feb 3, 2021 | clinicaltrials |
| NCT00662597 | ASA404 or Placebo in Combination With Paclitaxel and Carboplatin as First-Line Treatment for Stage IIIb/IV Non-Small Cell Lung Cancer(ATRACT-1) | terminated | Phase 3 | 1,285 | Novartis PharmaceuticalsINDUSTRY | 26 | Dec 24, 2020 | clinicaltrials |
| NCT00738387 | A Study of ASA404 or Placebo in Combination With Docetaxel in Second-line Treatment for (Stage IIIb/IV) Non-small Cell Lung Cancer(ATTRACT-2) | terminated | Phase 3 | 900 | Novartis PharmaceuticalsINDUSTRY | 10 | Dec 24, 2020 | clinicaltrials |
| NCT00480025 | GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer | terminated | Phase 3 | 2,278 | GlaxoSmithKlineINDUSTRY | 34 | Dec 22, 2020 | clinicaltrials |
| NCT03516084 | A Study of Niraparib as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer | terminated | Phase 3 | 185 | Zai Lab (Shanghai) Co., Ltd.INDUSTRY | 1 | Dec 21, 2020 | clinicaltrials |
| NCT00269828 | A Survival Study for Women With Advanced Lung Cancer Who Have Not Previously Received Chemotherapy.(PIONEER) | terminated | Phase 3 | 600 | CTI BioPharmaINDUSTRY | 11 | Nov 24, 2020 | clinicaltrials |
| NCT00054184 | Polyglutamate Paclitaxel Compared With Docetaxel in Treating Patients With Progressive Non-Small Cell Lung Cancer | terminated | Phase 3 | 350 | CTI BioPharmaINDUSTRY | 1 | Oct 5, 2020 | clinicaltrials |
| NCT00054197 | Polyglutamate Paclitaxel Compared With Gemcitabine or Vinorelbine in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer | terminated | Phase 3 | — | CTI BioPharmaINDUSTRY | 1 | Oct 5, 2020 | clinicaltrials |
| NCT00054210 | Polyglutamate Paclitaxel Plus Carboplatin Compared With Paclitaxel Plus Carboplatin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer | terminated | Phase 3 | — | CTI BioPharmaINDUSTRY | 2 | Oct 5, 2020 | clinicaltrials |
| NCT00551733 | Carboplatin With Either Paclitaxel Poliglumex or Paclitaxel in Treating Women With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer | terminated | Phase 3 | 450 | CTI BioPharmaINDUSTRY | 1 | Oct 5, 2020 | clinicaltrials |
| NCT03745222 | A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung Cancer(RATIONALE001) | terminated | Phase 3 | 1 | CelgeneINDUSTRY | 23 | Jul 15, 2020 | clinicaltrials |
| NCT02004184 | Pemetrexed in Advanced Non-Small-Cell Lung Cancer: at Progression vs Maintenance Therapy After Induction Chemotherapy(IDA) | terminated | Phase 3 | 230 | Norwegian University of Science and TechnologyOTHER | 1 | Jun 23, 2020 | clinicaltrials |
| NCT01774578 | Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer | terminated | Phase 2 / Phase 3 | 135 | NewLink Genetics CorporationINDUSTRY | 1 | May 28, 2020 | clinicaltrials |
| NCT02926638 | Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches | terminated | Phase 2 / Phase 3 | 9 | SWOG Cancer Research NetworkNETWORK | 1 | Mar 19, 2020 | clinicaltrials |
| NCT01902823 | Effect of Cancer Nurse Navigators on Patient Outcomes | terminated | Phase 2 / Phase 3 | 16 | University of Wisconsin, MadisonOTHER | 1 | Dec 13, 2019 | clinicaltrials |
| NCT02187367 | Safety & Efficacy Study of EGF Cancer Vaccine to Treat Stage IV Biomarker Positive, Wild Type EGF-R NSCLC Patients(EGF) | terminated | Phase 3 | 106 | Bioven EuropeINDUSTRY | 11 | Sep 10, 2019 | clinicaltrials |
| NCT03348904 | Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer | terminated | Phase 3 | 2 | Incyte CorporationINDUSTRY | 1 | Jun 13, 2019 | clinicaltrials |
| NCT02186301 | TIGER-1: Safety and Efficacy Study of Rociletinib (CO-1686) or Erlotinib in Patients With EGFR-mutant/Metastatic NSCLC Who Have Not Had Any Previous EGFR Directed Therapy(EGFR) | terminated | Phase 2 / Phase 3 | 100 | Clovis Oncology, Inc.INDUSTRY | 7 | May 7, 2019 | clinicaltrials |
| NCT02775006 | Docetaxel Versus Intercalated Erlotinib-docetaxel in Patients With Relapsed EGFR Wild Type, ALK Negative Non Squamous Cell Carcinoma | terminated | Phase 3 | 45 | The Netherlands Cancer InstituteOTHER | 1 | Apr 30, 2019 | clinicaltrials |
| NCT02409355 | A Study of Atezolizumab Compared With Gemcitabine Plus (+) Cisplatin or Carboplatin for PD-L1-Selected Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower111) | terminated | Phase 3 | 8 | Hoffmann-La RocheINDUSTRY | 14 | Feb 15, 2019 | clinicaltrials |
| NCT02162537 | Therapeutic Strategies in Patients With Non-squamous Non-small Cell Lung Cancer With Brain Metastases(METAL2) | terminated | Phase 3 | 95 | Centre Hospitalier Intercommunal CreteilOTHER | 1 | Feb 1, 2019 | clinicaltrials |
| NCT01446874 | Prevention of Post-operative Pneumonia (POPP)(POPP) | terminated | Phase 2 / Phase 3 | 150 | Washington University School of MedicineOTHER | 1 | Nov 8, 2018 | clinicaltrials |
| NCT01058759 | Taxotere-Enoxaparin-(ENOXA)-Study | terminated | Phase 3 | 14 | Hannover Medical SchoolOTHER | 1 | Aug 22, 2018 | clinicaltrials |
| NCT01041781 | Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer | terminated | Phase 3 | 313 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jul 23, 2018 | clinicaltrials |
| NCT01208064 | Pazopanib Hydrochloride or a Placebo in Treating Patients With Non-Small Cell Lung Cancer Who Have Received First-Line Chemotherapy | terminated | Phase 2 / Phase 3 | 102 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 8 | Jul 12, 2018 | clinicaltrials |
| NCT00096265 | Radiation Therapy and Stereotactic Radiosurgery With or Without Temozolomide or Erlotinib in Treating Patients With Brain Metastases Secondary to Non-Small Cell Lung Cancer | terminated | Phase 3 | 126 | National Cancer Institute (NCI)NIH | 2 | Mar 9, 2018 | clinicaltrials |
| NCT02134015 | Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung)(HER3-Lung) | terminated | Phase 3 | 145 | Daiichi SankyoINDUSTRY | 10 | Jan 23, 2018 | clinicaltrials |
| NCT02326285 | Induction Therapy With Intercalated Tyrosine Kinase Inhibitor (TKI) and Chemotherapy in NSCLC With Activating Epidermal Growth Factor Receptor (EGFR) Mutation in Stages II-IIIB(NeoIntercal) | terminated | Phase 2 / Phase 3 | 1 | AIO-Studien-gGmbHOTHER | 1 | Jan 23, 2018 | clinicaltrials |
| NCT02049151 | Tecemotide Following Concurrent Chemo-radiotherapy for Non-small Cell Lung Cancer(START2) | terminated | Phase 3 | 35 | EMD SeronoINDUSTRY | 2 | Aug 23, 2017 | clinicaltrials |
| NCT02178397 | A Multicenter Randomized Phase III Study Comparing Second-line Treatment With Chemotherapy Associated or Not to Erlotinib in NSCLC Patients With Secondary Resistance to TKI-EGFR(FLARE) | terminated | Phase 3 | 6 | Centre Francois BaclesseOTHER | 1 | Jul 17, 2017 | clinicaltrials |
| NCT01336894 | Surgery With or Without Internal Radiation Therapy Compared With Stereotactic Body Radiation Therapy in Treating Patients With High-Risk Stage I Non-Small Cell Lung Cancer | terminated | Phase 3 | 13 | Alliance for Clinical Trials in OncologyOTHER | 2 | May 30, 2017 | clinicaltrials |
| NCT00300495 | Study of Amiodarone Given Before Lung Surgery to Prevent Atrial Fibrillation After Lung Resection | terminated | Phase 3 | 19 | Beth Israel Deaconess Medical CenterOTHER | 1 | Apr 28, 2017 | clinicaltrials |
| NCT00526643 | CAPPA-2: Cisplatin Added to Gemcitabine in Poor Performance Advanced NSCLC Patients(CAPPA-2) | terminated | Phase 3 | 57 | National Cancer Institute, NaplesOTHER | 1 | Mar 28, 2017 | clinicaltrials |
| NCT00863512 | Chemotherapy or Observation in Treating Patients With Early Stage Non-Small Cell Lung Cancer | terminated | Phase 3 | 34 | Alliance for Clinical Trials in OncologyOTHER | 2 | Mar 27, 2017 | clinicaltrials |
| NCT01319669 | Clinical Trial on the Prevention of Thrombocytopenia After First-line Chemotherapy | terminated | Phase 2 / Phase 3 | 11 | Chinese Society of Lung CancerOTHER | 1 | Mar 3, 2017 | clinicaltrials |
| NCT01383148 | Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer(TIME) | terminated | Phase 2 / Phase 3 | 222 | TransgeneINDUSTRY | 10 | Jan 5, 2017 | clinicaltrials |
| NCT01377376 | A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study of ARQ 197 Plus Erlotinib Versus Placebo Plus Erlotinib(ATTENTION) | terminated | Phase 3 | — | Kyowa Kirin Co., Ltd.INDUSTRY | 1 | Dec 7, 2016 | clinicaltrials |
| NCT01015443 | Cancer Vaccine Study for Stage III, Unresectable, Non-small Cell Lung Cancer (NSCLC) in the Asian Population(INSPIRE) | terminated | Phase 3 | 285 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 5 | Oct 26, 2016 | clinicaltrials |
| NCT00190476 | Elderly NSCLC/D vs DP (JCOG0207) | terminated | Phase 3 | 230 | Japan Clinical Oncology GroupOTHER | 1 | Sep 12, 2016 | clinicaltrials |
| NCT01798485 | A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC(Galaxy 2) | terminated | Phase 3 | 696 | Synta Pharmaceuticals Corp.INDUSTRY | 20 | Jul 1, 2016 | clinicaltrials |
| NCT00812266 | Topotecan and Cisplatin Versus Etoposide and Carboplatin in 1st Line Treatment of Patients With Small Cell Lung Cancer and Extensive Disease (SCLC-ED) | terminated | Phase 3 | 281 | Danish Oncological Lung Cancer GroupOTHER | 1 | Jan 26, 2016 | clinicaltrials |
| NCT00345059 | The DISTAL-2 Study: Docetaxel Alone or in Combination in Second-line Treatment of Advanced Non Small-Cell Lung Cancer(DISTAL-2) | terminated | Phase 3 | 84 | National Cancer Institute, NaplesOTHER | 1 | Jan 14, 2016 | clinicaltrials |
| NCT02629848 | Study of Motesanib (AMG 706) in Combination With Paclitaxel and Carboplatin for Advanced Non-Squamous Non-Small Cell Lung Cancer | terminated | Phase 3 | 401 | TakedaINDUSTRY | 0 | Dec 14, 2015 | clinicaltrials |
| NCT01348126 | Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung Cancer(GALAXY) | terminated | Phase 2 / Phase 3 | 385 | Synta Pharmaceuticals Corp.INDUSTRY | 13 | Nov 5, 2015 | clinicaltrials |
| NCT00738881 | Pemetrexed Disodium or Erlotinib Hydrochloride as Second-Line Therapy in Treating Patients With Advanced Non-small Cell Lung Cancer(MARVEL) | terminated | Phase 3 | 23 | National Cancer Institute (NCI)NIH | 2 | Oct 29, 2015 | clinicaltrials |
| NCT00460317 | MONET1-MOtesanib NSCLC Efficacy and Tolerability Study | terminated | Phase 3 | 1,450 | AmgenINDUSTRY | 0 | Sep 7, 2015 | clinicaltrials |
Data updated 23 days agoSource updated Jun 2, 2021source: clinicaltrials